PVNS is a rare, benign, but locally aggressive neoplastic process characterized by the proliferation of the synovium in joints, tendon sheaths, and bursae. It is characterized by the deposition of hemosiderin, which gives the tissue a characteristic brown/rust color and a unique signature on advanced imaging. For the board-certified physician, the key is recognizing the “bloody” aspirate in a non-traumatic setting and the specific MRI artifacts that define the disease.

1. Classification and Location

PVNS is generally categorized into two forms:

• Diffuse Form: Involves the entire synovium of a joint. The knee is the most common site (80% of cases), followed by the hip and ankle. This form is more aggressive and has a high recurrence rate.
• Localized (Localized TGCT): Usually involves the tendon sheaths of the hand or foot. It presents as a slow-growing, painless mass, often referred to as a “Giant Cell Tumor of the Tendon Sheath.”

2. Clinical Presentation: The “Spontaneous” Swelling

Patients typically present in their 20s to 50s.

• Recurrent Monoarthritis: Chronic, persistent joint swelling and pain.
• Mechanical Symptoms: Catching or locking that may mimic a meniscal tear.
• Non-Traumatic Hemarthrosis: The hallmark clinical finding. The patient presents with a “bloody” joint effusion but denies any recent injury or falls.

3. Pathophysiology: The Role of CSF1

PVNS is driven by a specific genetic translocation involving the CSF1 (Colony Stimulating Factor 1) gene.

• Hemosiderin Deposition: The hyperplastic synovial cells bleed easily, leading to the accumulation of iron-rich hemosiderin within the tissue. This iron is what creates the “pigmented” appearance and the specific MRI findings.

4. High-Yield Diagnostic Findings

Synovial Fluid Analysis

• Appearance: Xanthochromic (dark yellow) or serosanguinous (dark, “cola-colored” or chocolatey blood).
• Differential: This must be distinguished from hemophilia or trauma. In PVNS, the blood is typically older and darker.

MRI: The “Blooming” Artifact

This is the most likely way PVNS is tested on boards.

• T1 and T2 Weighting: The hemosiderin appears as low-signal (dark) areas within the thickened synovium.
• Gradient Echo (GRE) Sequences: This is the high-yield sequence. Because hemosiderin is paramagnetic, it causes a “magnetic susceptibility” effect. On GRE sequences, the dark areas appear to “expand” or get larger than they actually are. This is known as the “Blooming Artifact.”

5. Management: Surgical and Targeted Therapy

• Synovectomy: The primary treatment. For the diffuse form, an open or arthroscopic total synovectomy is required. However, recurrence rates are high (up to 50%).
• Radiation Therapy: Sometimes used as an adjunct for refractory diffuse cases.
• CSF1R Inhibitors: A breakthrough in TGCT/PVNS management. Drugs like Pexidartinib (a CSF1 receptor antagonist) are now FDA-approved for symptomatic patients who are not candidates for surgery.

6. Post-Op Rehabilitation

The challenge is managing a “stiff” joint after a total synovectomy.

• Early Mobilization: Essential to prevent arthrofibrosis.
• Long-Term Monitoring: Because of the high recurrence rate, any new-onset swelling in a patient with a history of PVNS should be treated as a recurrence until proven otherwise.
• Joint Preservation: Chronic PVNS leads to early-onset, severe osteoarthritis. Physiatry focuses on joint-sparing activities (cycling, swimming) to delay the need for joint replacement.

---

High-Yield Board “Fast Facts”

• Non-Traumatic Hemarthrosis: “Cola-colored” or bloody fluid without an injury.
• Blooming Artifact: Pathognomonic MRI finding on Gradient Echo (GRE) sequences.
• Hemosiderin: The iron-rich pigment responsible for the MRI findings and tissue color.
• Knee: The most common location.
• CSF1 Translocation: The underlying genetic driver of the disease.